Biotome is an Australian biotechnology company developing next-generation antibody diagnostics through epitope-level precision. Our proprietary platform analyzes immune responses to specific protein fragments (epitopes) rather than whole antigens, delivering superior specificity and sensitivity compared to conventional serology.
Our lead product, Helitope™, is the world's first blood test to stratify gastric cancer risk by detecting antibodies against specific Helicobacter pylori virulence factor epitopes. This breakthrough diagnostic identifies H. pylori-infected individuals at highest risk for gastric adenocarcinoma, enabling targeted prevention strategies. The technology is protected by patents granted in 20 countries.
Beyond our diagnostic pipeline, we provide epitope mapping services to vaccine developers, diagnostic companies, and therapeutic antibody researchers worldwide. Our platform combines proprietary peptide-ELISA technology, advanced bioinformatics pipelines, and deep immunoproteomics expertise to deliver actionable insights for antibody-based applications.
Why work with us
Technical Excellence That Delivers Results
Unmatched Epitope Resolution
Our platform achieves single-epitope resolution, enabling discrimination between closely related immune responses that whole-protein methods miss. We've validated performance across >350,000 unique peptides.
Proven Track Record
We've successfully translated epitope discovery into commercial diagnostics. Our gastric cancer risk marker demonstrates the real-world impact of precision serology – from initial discovery through international patent protection and clinical validation.
Comprehensive Capabilities
- Linear and conformational epitope mapping for complete antibody characterization
- Multiplexed peptide arrays for simultaneous profiling of entire antibody repertoires
- Cross-reactivity analysis for high-specificity biomarkers
- Machine learning algorithms for B-cell epitope prediction and clinical correlation
Applications Across Your Research Pipeline
Vaccine Development
- Map protective vs non-protective epitopes to optimize antigen design
- Identify conserved epitopes across pathogen strains for broad coverage
- Distinguish vaccine-induced from natural infection antibodies
- Characterize epitope-specific responses in clinical trials
Therapeutic Antibody Programs
- Precise epitope binning for lead optimization
- Comprehensive cross-reactivity profiling for safety assessment
- Freedom-to-operate analysis based on epitope-level IP landscape
- Companion diagnostic development using validated epitope markers
Diagnostic Development
- Identify disease-specific antibody signatures with minimal cross-reactivity
- Develop multiplexed assays using synthesized peptide antigens
- Reduce costs compared to recombinant protein production
- Access our patent-pending universal peptide-ELISA platform for commercialisation
Autoimmune Disease Research
- Systematic mapping of autoantigen epitopes
- Patient stratification based on epitope-specific autoantibody profiles
- Monitor epitope spreading during disease progression
- Validate targets for tolerogenic therapeutic approaches
Partnership Advantages
When you work with Biotome, you gain:
- Experienced team with proven expertise in immunoproteomics, clinical diagnostics development, and regulatory affairs
- IP strategy guidance based on our successful international patent portfolio
- Scalable solutions from research-phase epitope discovery through commercial diagnostic development
- Cost-effective approach using peptide antigens instead of expensive recombinant proteins
- Rapid turnaround with established protocols and automated workflows
Our deep understanding of both the science and commercial development of precision serology ensures your project benefits from insights we've gained developing our own diagnostic products.
